METHOTREXATE IN THE MANAGEMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS

S SAEED; M SAEED; S ASLAM; Z LIAQAT; N DAWOOD; OM SAFDAR

doi:10.54112/bcsrj.v2023i1.547

Authors

S SAEED Respiratory Ward, Good Hope Hospital Birmingham, United Kingdom
M SAEED Department of Dermatology, Faisalabad Medical University Faisalabad, Pakistan
S ASLAM Department of Dermatology, District Headquarter Hospital Layyah, Pakistan
Z LIAQAT Department of Dermatology, Avicenna Medical College and Teaching Hospital Lahore, Pakistan
N DAWOOD Department of Dermatology, Dr.Sulaiman Al Habib Medical Group Khobar, Saudia Arab
OM SAFDAR Specialist Dermatologist, Dr.Sulaiman Al Habib Medical Group Khobar, Saudia Arab

DOI:

https://doi.org/10.54112/bcsrj.v2023i1.547

Keywords:

Atopic Dermatitis, Methotrexate, Skin inflammtion

Abstract

The retrospective study was conducted in the Department of Dermatology from June 2021 to June 2022 to analyze the complication profile, adverse effects, and efficacy of methotrexate in patients with moderate to severe AD. The patients with moderate to severe AD were included in the study. The demographic data, clinical records, and response to MTX were analyzed. The clinical response was assessed as a decrease in itching, improvement in skin lesions, lesser use of topical CS, and assessment by the dermatologist. During the treatment, the patient's renal function, liver function, and complete blood count were assessed every month for three months. The study was conducted on 40 patients (17 female, 23 male). The mean starting dose was 13.8mg. The mean maintenance dose was 17.8 mg. The dose was gradually tapered after control of symptoms. 28 (70%) patients had clear responses, 7 (17.5%) had excellent, 3 (7.5%) had good, and 2(5%) patients had partial response. The mean duration of MTX therapy was 36.9 months. Due to disease control, MTX was discontinued in 8 (17.5%) patients. 4 (10%) patients remained clear, and treatment was restarted in 3 (7.5%) patients due to flare. Thirty-two patients were still on treatment at the time of the study. Nausea occurred in 4(10%) patients, fatigue in 3 (7.5%) and a transient increase in transaminases in 7 (17.5%) patients. 1 (2.5%)patient had a transient decrease in hemoglobin and platelet level; Hb was maintained at 106-120 g/L, and platelet level became normal. Methotrexate is safe and effective for the treatment of moderate to severe AD. Lower doses can control disease in the long term without posing any significant risks.

Downloads

Download data is not yet available.

References

Barak Levitt, J. A., Alemi, S., Ollech, A., Reiss-Huss, S., Sah, M., Renert-Yuval, Y., Friedland, R., Greenberger, S., and Cohen Barak, E. (2023). Treatment with Methotrexate in Infants and Toddlers with Atopic Dermatitis: A Retrospective Multi-Center Study. Journal of Clinical Medicine 12, 5409.

Davari, D. R., Nieman, E. L., McShane, D. B., and Morrell, D. S. (2021). Current perspectives on the systemic management of atopic dermatitis. Journal of Asthma and Allergy, 595-607.

Drucker, A. M., Morra, D. E., Prieto-Merino, D., Ellis, A. G., Yiu, Z. Z., Rochwerg, B., Di Giorgio, S., Arents, B. W., Burton, T., and Spuls, P. I. (2022). Systemic immunomodulatory treatments for atopic dermatitis: update of a living systematic review and network meta-analysis. JAMA dermatology.

Flohr, C., Rosala-Hallas, A., Jones, A. P., Beattie, P., Baron, S., Browne, F., Brown, S. J., Gach, J. E., Greenblatt, D., and Hearn, R. (2023). Efficacy and safety of ciclosporin versus methotrexate in the treatment of severe atopic dermatitis in children and young people (TREAT): a multicentre, parallel group, assessor-blinded clinical trial. British Journal of Dermatology, ljad281.

Giavina-Bianchi, M., and Giavina-Bianchi, P. (2019). Systemic treatment for severe atopic dermatitis. Archivum immunologiae et therapiae experimentalis 67, 69-78.

Hernández‐Martín, A., Noguera‐Morel, L., Bernardino‐Cuesta, B., Torrelo, A., Pérez‐Martin, M., Aparicio‐López, C., and de Lucas‐Collantes, C. (2017). Cyclosporine A for severe atopic dermatitis in children. efficacy and safety in a retrospective study of 63 patients. Journal of the European Academy of Dermatology and Venereology 31, 837-842.

Kimler, K. A., McDonald, D., and Shah, P. B. (2019). Treatment of Atopic Dermatitis in Pediatric Patients: Nursing Implications. Pediatric Nursing 45.

Navarro-Triviño, F. J., Galán-Gutiérrez, M., Hita, J. C.-A., Ruiz-Villaverde, R., Domínguez-Cruz, J., and Pereyra-Rodríguez, J. J. (2023). Real-World Clinical Experience of Dupilumab in the Treatment of Chronic Palmo-Plantar Eczema in Patients with Moderate-Severe Atopic Dermatitis: 52-Week Follow-Up. Dermatitis®.

Patro, N., Panda, M., and Dash, M. (2020). Cyclosporine a in recalcitrant pediatric dermatoses–A retrospective analysis of thirty children. Indian Journal of Paediatric Dermatology 21, 98-104.

Purvis, D., Lee, M., Agnew, K., Birchall, N., and Dalziel, S. R. (2019). Long‐term effect of methotrexate for childhood atopic dermatitis. Journal of Paediatrics and Child Health 55, 1487-1491.

Seger, E. W., Wechter, T., Strowd, L., and Feldman, S. R. (2019). Relative efficacy of systemic treatments for atopic dermatitis. Journal of the American Academy of Dermatology 80, 411-416. e4.

Shamim, H., Rana, M., Hanif, S., and Sultan, N. (2023). Comparison of efficacy of methotrexate and azathioprine in chronic resistant atopic eczema. Journal of Pakistan Association of Dermatologists 33, 1057-1061.

Singh, M., Coulton, A., King, T., Salam, A., Sharma, M., Griffiths, T., and Cohen, S. (2021). The British association of dermatologists' undergraduate curriculum update 2021. Clinical and Experimental Dermatology 46, 710-714.

Voorberg, A. N., Kamphuis, E., Christoffers, W. A., Romeijn, G. L., Oosterhaven, J. A., and Schuttelaar, M. L. (2022). Efficacy and safety of oral alitretinoin versus oral azathioprine in patients with severe chronic hand eczema: Results from a prematurely discontinued randomized controlled trial. Contact Dermatitis 87, 366.

Wollenberg, A., Deleuran, M., and Ring, J. (2019). Methotrexate in atopic eczema-Reply to a letter. Journal of the European Academy of Dermatology and Venereology: JEADV 33, e155-e156.